NCT05761977Active, not recruiting
Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer
Durvalumab in Combination With Standard Chemotherapy for 1st Line Therapy of Patients With Extensive Stage Small Cell Lung Cancer: A Non-interventional, Prospective Observational Study of Clinical Practice, Quality of Life and Use of Health Resources in Real-world Clinical Practice (DRIVE)
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
This is a non-interventional, multicenter, prospective observational study and registry of standard clinical practice in patients with Extensive Stage-Small Cell Lung Cancer (ES-SCLC) receiving 1st line treatment with Durvalumab in combination with standard chemotherapy (cisplatin or carboplatin + etoposide) in the approved indication, which will be carried out in Greece. In this study data will be collected prospectively based on real-world clinical practice. A prospective cohort of atients from centers of the Hellenic Cooperative Oncology Group (HeCOG) will be included. The study will be conducted in hospitals and by physicians specialized in lung cancer from different geographical areas of Greece.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 7 Feb 2023
- Start date
- 31 Mar 2021
- Primary completion date
- 15 Jan 2026
- Lead sponsor
- Hellenic Cooperative Oncology Group
- Diseases
- Lung cancer
- NCT number
- NCT05761977
What you commit to
- Study type: Observational
- Planned participants: 50
- From 31 Mar 2021 to the primary completion date, 15 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have previously received chemotherapy or immunotherapy for SCLC
- Patients who are currently receiving or are expected to receive treatment with an investigational drug/medical device/intervention or who have received an investigational medicinal product within 1 month or 5 years half-life of the research agent (whichever is longer) before their initiation in this study.
Other illness
- Patients with current diagnosis of primary cancer other than SCLC who require systemic or other treatment.
Who the study is looking for
- Male or female patients, regardless of race (residents in Greece), no younger than 18 years old at the initiation of treatment.
- Patients with histologically or cytologically confirmed diagnosis of extensive Small Cell Lung Cancer (SCLC)
- Patients who have not received prior systemic treatment for SCLC (chemotherapy or immunotherapy)
- Patients for whom the decision to administer treatment with Durvalumab+chemotherapy has already been taken before their inclusion in the study and is clearly separated from the decision of the physician for the patient's participation in the current study.
- Patients who have provided informed signed consent to participate in the study and to collect and analyze medical data related to the objectives of this study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Metropolitan Hospital Coordinator of this site? Confirm its status | Neo Faliro | Greece | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.